HHM Wealth Advisors LLC Has $242,000 Stock Position in Medtronic plc (NYSE:MDT)

HHM Wealth Advisors LLC lessened its holdings in Medtronic plc (NYSE:MDT) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,024 shares of the medical technology company’s stock after selling 317 shares during the period. HHM Wealth Advisors LLC’s holdings in Medtronic were worth $242,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Willis Investment Counsel lifted its position in shares of Medtronic by 0.5% in the fourth quarter. Willis Investment Counsel now owns 353,687 shares of the medical technology company’s stock worth $28,253,000 after buying an additional 1,837 shares during the last quarter. CENTRAL TRUST Co raised its stake in shares of Medtronic by 4.0% in the 4th quarter. CENTRAL TRUST Co now owns 10,478 shares of the medical technology company’s stock valued at $837,000 after acquiring an additional 402 shares in the last quarter. River Street Advisors LLC lifted its holdings in Medtronic by 2.2% in the 4th quarter. River Street Advisors LLC now owns 12,161 shares of the medical technology company’s stock worth $971,000 after purchasing an additional 267 shares during the last quarter. Greenleaf Trust boosted its position in Medtronic by 9.1% during the fourth quarter. Greenleaf Trust now owns 14,095 shares of the medical technology company’s stock worth $1,126,000 after purchasing an additional 1,174 shares during the period. Finally, Avantra Family Wealth Inc. acquired a new position in Medtronic during the fourth quarter valued at approximately $815,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

NYSE:MDT opened at $90.55 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.39 and a current ratio of 1.84. The company has a 50-day moving average of $84.38 and a 200-day moving average of $86.09. Medtronic plc has a 52 week low of $75.96 and a 52 week high of $93.08. The company has a market capitalization of $116.11 billion, a price-to-earnings ratio of 27.69, a PEG ratio of 2.57 and a beta of 0.84.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The company had revenue of $8.40 billion for the quarter, compared to the consensus estimate of $8.27 billion. During the same period in the previous year, the business earned $1.25 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, equities research analysts anticipate that Medtronic plc will post 5.45 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Friday, December 27th were issued a dividend of $0.70 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.09%. Medtronic’s payout ratio is presently 85.63%.

Insider Buying and Selling at Medtronic

In other news, EVP Brett A. Wall sold 12,437 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $90.00, for a total value of $1,119,330.00. Following the transaction, the executive vice president now directly owns 40,979 shares of the company’s stock, valued at $3,688,110. The trade was a 23.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Royal Bank of Canada raised shares of Medtronic from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $98.00 to $105.00 in a report on Thursday, October 10th. Sanford C. Bernstein upped their price target on shares of Medtronic from $96.00 to $97.00 and gave the company an “outperform” rating in a report on Wednesday, November 20th. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research note on Monday, November 18th. Barclays increased their target price on Medtronic from $105.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. Finally, Wells Fargo & Company dropped their price target on Medtronic from $106.00 to $98.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $95.00.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.